Compare Amgen, Inc. (AMGN) vs Starbucks Corp (SBUX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Starbucks Corp — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Starbucks Corp trades at $106.09 (market cap $120.82B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | SBUX | |
|---|---|---|
Market Cap | $196.12B | $120.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $106.82 |
52-Week Low | $271.18 | $78.46 |
Enterprise Value | $241.41B | $143.51B |
Dividend Yield | 2.77% | 2.34% |
Volume | — | 7,493,833 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Starbucks (SBUX) trades at $106.01, down 0.38% today, with a bullish technical signal and recent earnings beat in Q1 2026. The company's revenue grew to $37.18B in 2025, though net income margin compressed to 3.89%. Recent news highlights AI initiatives to cut software costs, while analyst consensus is split evenly between Buy and Hold ratings with a $107.67 price target.
Outlook remains mixed: AI cost savings and loyalty growth offer upside, but margin pressure and high P/E of 80.92 pose risks. Near-term performance hinges on Q2 2026 earnings versus the $0.65 EPS estimate and execution of operational efficiencies amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
